INTRODUCTION
A number of nucleoside analogues have been used successfully both as anticancer and antiviral agents for many years. Unfortunately, these drugs have toxic side effects that concern essentially proliferating tissues (i.e. bone marrow and gastrointestinal tract) when the nucleoside analogues are given over short periods, or damage to mitochondrial function when the drugs must be given over long periods of time [1] . 2',3'-Dideoxycytidine (ddC) is one ofthe most potent human immunodeficiency virus (HIV) inhibitors in vitro [2] and has shown beneficial effects in patients with acquired immune deficiency syndrome (AIDS) [3] . After several weeks on ddC treatment, some patients develop a peripheral neuropathy [4] . Studies in vitro have strongly suggested that the depletion of mitochondrial DNA (mDNA) could be responsible for the delayed toxicity of ddC observed clinically [5, 6] . This depletion of mDNA may be due to inhibition of DNA polymerase y by 2',3'-dideoxycytidine 5'-triphosphate (ddCTP) [7] . The cytoplasmic ddC kinase seems to be the enzyme responsible for the initial phosphorylation of ddC [6] , and in turn for ddC toxicity.
Two additional problems are associated with the use of reverse transcriptase (RT) inhibitors and are likely to contribute to the failure of existing therapies in completely blocking clinical progression of AIDS. The first reason why individuals progress to disease while on antiretrovirals can be found in the frequent changes of HIV genomic sequences in the same patient due to the high error rate of RT; the second reason is probably the failure to maintain adequate drug levels in any potential site of viral replication over long periods [8] . Although RT mutations that confer resistance to the nucleoside analogues have been investigated [9, 10] , drug metabolism in cells and tissues maintained at adequate drug concentrations for extended periods has been poorly studied. In this paper we have investigated ddC toxicity in U937 human monoblastoid cells exposed to the drug for several triphosphate (ddCTP) formation in U937-R cells was almost one-third of that measured in normal cells, although the rate of ddCTP catabolism was similar in both cell lines. Dideoxyliponucleotide (ddCDP-choline and ddCDP-ethanolamine) formation was also much slower (between one-half and one-third as fast) in U937-R than in control cells, although catabolism occurred at similar rates. ddC was phosphorylated by a cytoplasmic deoxycytidine kinase in both cell lines. This enzyme showed K. values for ddC of 80 + 7 and 140 + 9 1tM in U937 and U937-R cells respectively. Furthermore, Vmax was 12 + 1.1 and 7.8 + 0.5 pmol/min per mg of protein in U937 and U937-R. Thus resistance to ddC toxicity may be due to cells' decreased ability to accumulate intracellular ddC anabolites, which may depend on cytoplasmic deoxycytidine kinase.
weeks. Furthermore, we have shown that it is possible to isolate ddC-resistant cells (U937-R) with high frequency and that the resistance to ddC toxicity is associated with a reduced cell ability to accumulate intracellular ddC anabolites. [5,6-3H] Dideoxycytidine incorporation into phosphorylated metabolites was measured by incubation of U937 and U937-R cells at a density of 0.8 x 106 to 1.0 x 106 cells per ml in six-well plates in the presence of different ddC concentrations and for different incubation times (1-48 h). At each time and for each concentration tested, duplicate cell samples were harvested by centrifugation after the addition of an excess of ice-cold PBS, after which the radioactive culture media was decanted and the cell pellets were extracted with 250 ,1 of 5 % (v/v) HCl04. The HC104 extract was neutralized with K2C03 as reported in [12] , for analysis by HPLC to determinate metabolic products of ddC. Total phosphorylated metabolites of ddC were measured by adsorption of neutralized HC104 extracts on DE-81 filter discs that were washed and counted as in [13] . ddC incorporated into DNA was determined as in [12] .
EXPERIMENTAL PROCEDURES
HPLC chromatography was done on a 3 ,um Supelcosil LC-18T column (15 25 min and hold for 5 min. The gradient was returned to 100 % buffer A over 2 min and the initial conditions restored over 4 min. The flow rate was 1.0 ml/min and the detection wavelength was 272 nm. Analyses were performed at room temperature and quantitative measurements were obtained by injection of a standard of known concentration. The molar absorption value used for standard calibration of ddC, ddCMP, ddCDP and ddCTP at 272 nm was 9.1. The retention times for ddC, ddCMP, ddCDP and ddCTP were 9.5, 10.5, 11.5 and 17.0 min respectively. Fractions (0.3 ml) were collected at the exit of the wavelength detector with an LKB fraction collector and counted in a Packard 1500 liquid scintillation counter.
ddC transport measurements
Assays of ddC influx into U937 and U937-R cells were performed at 37°C in 1.5 ml polypropylene microcentrifuge tubes, using an 'oil-stop' method [14] . Uptake intervals were initiated by the rapid addition of 350 #u1 of cell suspension (5 x 105 cells) to an equal volume of 3H-permeant solution layered over 600 ,ul of 1-bromododecane in 1.5 ml microcentrifuge tubes. Uptake was ended by centrifugal pelleting of the cells at 20 s intervals. The 3H content of cell pellets was measured as in [14] . The amount of extracellular medium in the cell pellet was determined with [U-14C]sucrose as previously reported [15] . Initial velocities were determined during the linear phase of influx, which was within 2 min. [3H]dC. Incubation was for 1 h at 37 'C. The assay was linear during this time. An aliquot of the reaction mixture (100 ,ul) was spotted on to a DE-81 disc, washed 3 times with 1 mM ammonium formate, once with water and once with ethanol as in Ref. [16] , and counted in a fl-counter (Packard Model 1500). Km values were determined from double-reciprocal plots (V-1 against S 1).
ddC phosphorylation was determined on cell-free high-speed supernatants and intact mitochondria. Briefly, cells were resuspended in 9 volumes of 220 mM mannitol, 70 mM sucrose, 0.2 mM EDTA, 2 mM Hepes, pH 7.4 (homogenizing buffer), and homogenized by a Dounce glass homogenizer. The homogenate was centrifuged first at 1500 g to pellet unbroken cells and nuclei, then at 12000 g to obtain the mitochondrial fraction; this supernatant was finally centrifuged at 105000 g to obtain the cell-free high-speed supernatant. All centrifugations were at 4 'C for 30 min. Protein content was determined by Bradford's protein assay reagent (Bio-Rad).
RESULTS
Delayed cytotoxicity and mitochondrial DNA content U937 cells grew normally in the presence of 0.25-1 ,uM ddC for 4-5 days (Figure la) . After this time, cell growth was inhibited and cells died in a couple of weeks, as has already been reported for Molt-4F cells [5] . Total cellular DNA was extracted from U937 at day 2, 5, 9, 13 and 17 after ddC addition. The DNA was digested with the restriction enzyme BamHI, which linearizes the experiment such as that shown in Figure 2 , 22 days after ddC addition, were stained with Rh-123. As shown in Figure 3 , although almost all the cells are highly fluorescent in the absence of ddC, most are no longer stained if maintained in the presence of 1 ,uM ddC. An intermediate situation was found when 0.1 pM ddC was used. The kinetics of the process (Figure 3b) clearly show that after 4-5 weeks in the presence of 0.1 ,uM ddC most of the cells became stained by the dye, whereas most cells at 1 ,uM ddC died and the few remaining did not recover the initial fluorescence. The results shown in Figure 4 demonstrate that the cells that are selected for their resistance to 0.1 ,M ddC toxicity have indeed acquired resistance to the drug. U937 cells, after 2 months of growth in the presence of 0.1 ,uM ddC (U937-R), were cultured for a further month in the presence of 1 pM ddC. Normal U937 cells died after 2-3 weeks at this drug concentration (see above), whereas U937-R cells continued to grow with a proliferative index 50 + 3 % of that of controls, contained a higher mDNA content than controls, and stained normally with Rh-123 (Figure 4 uptake of ddC and formation of its phosphorylated metabolites was higher in U937 than in U937-R cells (Figure 5a ), although the incorporation of ddC into nucleic acid was similar (Figure 5b ), suggesting that delayed cytotoxicity of ddC may not be due to incorporation of the drug into nuclear DNA. When the acidsoluble fractions of U937 and U937-R cells incubated for 24 h with 10 #M [3H]ddC were analysed by ion-pair HPLC chromatography ( Figure 6 ), four major peaks of radioactivity were found. The metabolite eluted at 17 min was in a position identical to authentic ddCTP. ddC, ddCMP and ddCDP eluted at 9.5-12 min and could not be measured individually in the fractions collected at the exit of the wavelength detector. Metabolites of ddC that eluted at 4 and 7 min respectively were tentatively identified as ddCDP-choline and ddCDP-ethanolamine respectively on the basis of the elution positions of dCDP-choline and dCDPethanolamine and by the data obtained in other laboratories [18, 19] . It is worth noting that the ddCTP concentration in U937-R was 45 % of the controls and that both dideoxyliponucleotides were also markedly reduced. To determine whether these differences in ddC metabolites are peculiar properties of the ddCresistant cells, we repeated the determinations of Figure 6 at several tiaw points from. I to 48 h after ddC addition. As shown in Figure 7 , the rates of ddCTP and dideoxyliponucleotide formation were significantly reduced in the U937-R cells compared with controls. Figure 8 , the rates of ddCTP catabolism were similar (1.75 and 1.18 pmol/h per 106 cells) in both cell hnes, whereas the dideoxyliponucleotides showed a remarkable stabihty.
ddC Influx In U937 and U937-R cells
The influx of ddC in both cell lines was not concentrative (not shown). ddC influx was linear for approximately 2 min at 37 'C and showed no evidence of saturation in the range 1-500 ItM ( Figure 9 ). Thus differences in ddC transport cannot explain the acquired resistance of U937-R to ddC toxicity. dC kinase Both cytoplasmic deoxycytidine kinase and mitochondrial deoxypyrirnidine kinase have been reported to phosphorylate ddC to ddCMP [7] . Preliminary studies performed on intact, isolated mitochondria incubated with ddC have not revealed any detectable ddC phosphorylation (not shown), in agreement with previous reports [6] . In contrast, ddC is actively phosphorylated by cytosolic supernatants from high-speed centrifugation obtained both from U937 and U937-R. We therefore investigated the kinetic properties of cytoplasmic deoxycytidine kinase from both cell lines. As shown in Table 1 
DISCUSSION
A number of RT inhibitors with straightforward efficacy in vitro in inhibiting HIV infectivity are currently approved for use in treatment for HIV. Unfortunately, existing therapies based on RT inhibitors fail to block completely the clinical progression of the disease and spread of the virus (for reviews see [8, 22] [2] by cellular kinases. However, in many cases, the phosphorylated nucleoside analogues are also cytotoxic [1] , so the cells may develop specific drug-resistance mechanism(s). The mechanisms of decreased drug efficacy due to induction of resistance in treated cells are well known for the antitumour nucleoside analogues [23] .
Nothing is known about the possibility that similar mechanism(s) can also apply to the antiviral compounds of the dideoxynucleoside family.
In this paper we report that when cultured in the presence of 0.1 #tM ddC (a therapeutically relevant concentration), U937
human monoblastoid cells develop resistance to ddC. U937-R cells have a reduced ability to accumulate both ddCTP and dideoxyliponucleotides. This reduced anabolic activity is not caused by a defect in the influx of ddC in U937-R but by altered properties of the cytosolic deoxycytidine kinase. This conclusion seems to be supported by direct evidence that U937-R cells contain an enzyme with a reduced affinity for ddC, a smaller Vmax and a decreased Vmax/Km ratio. The affinity of the enzyme for dC was also diminshed but its Vmax was higher than in control cells and thus the Vmax/Km ratio was much less affected than in U937-R cells. Furthermore previous studies [6] on CEM/araC (a dC kinase-deficient cell line isolated for resistance to araC) have clearly shown that dC kinase-deficient cells are highly resistant to ddC mitochondrial toxicity. We have also noted that U937-R cells contain more mitochondria than normal cells (not shown). However, the mitochondrial DNA content per cell is slightly lower than in controls ( Figure 2 ). Thus it may be that both this reduced ability to accumulate ddC phosphorylated derivatives and the increased number of mitochondria per cell contribute to the mechanism of drug resistance in U937-R. The results reported in this paper also provide support to the mechanism of ddC toxicity suggested by Cheng [1, 6] . In fact, both ddC cytotoxicity and development of drug resistance are paralleled by a respective decrease and increase in the mitochondrial DNA content of U937 cells. Furthermore this cytotoxicity, which involves mitochondria, is not due to ddC phosphorylation in the mitochondrial compartment, but rather to cytosolic enzymes. Having shown that ddCTP is produced in the cytosol [6] , it remains to be investigated how this nucleotide analogue can penetrate the mitochondrial membrane. Although a ddCTP carrier has not yet been isolated, several lines of evidence suggest its existence. In fact, the metabolites of ddC, but not ddC itself, have been reported to inhibit mDNA synthesis in isolated mitochondria [6] , cytoplasmic dC kinase-deficient cells are highly resistant to mitochondrial toxicity by ddC [6] , and nucleoside analogues structurally and metabolically similar to ddC (i.e. 2',3'-dideoxy-3'-thiacytidine, 2',3'-dideoxy-L-5-fluorocytidine and 2',3'-dideoxy-L-cytidine) show no inhibition against mitochondrial DNA synthesis because they are not transported into the mitochondria [1, 24] . The identification of a carrier for ddCTP would prove useful in searching for possible inhibitors that might prevent the mitochondrial toxicity of ddC.
As shown in Figure 5 (b), some ddC is incorporated into nucleic acids. Starnes and Cheng [7] have already reported that ddC is incorporated into DNA. Incorporation of ddC into nucleic acids may be responsible for the inhibition of cell growth at high ddC concentrations (10-500,uM), as usually observed in short-term (2-3 days) exposure of cells to ddC [12] . At lower ddC concentrations, cells probably activate repair mechanisms for the removal of this nucleotide analogue from nuclear DNA. DNA polymerase y also has an associated 3' -* 5' exonuclease activity. However, DNA polymerase,B (the enzyme responsible for nuclear DNA repair) is inhibited by ddCTP with a K, of 1.2+0.2,uM, whereas DNA polymerase y is inhibited by ddCTP with a K, of 0.015 + 0.003 #M [25] . Thus the enzyme responsible for nuclear DNA repair is less sensitive to ddCTP inhibition than mitochondrial DNA polymerase y [261.
At present it is not known whether the mechanism of induced ddC resistance is also operating in vivo in patients undergoing long exposures to ddC. However, the data reported in this paper strongly suggest that ddC metabolism should be maintained in such patients after few months on ddC therapy. If ddC resistance is developed, alternative RT inhibitors, whose activation depends on different cellular enzymes, should be considered. [ddCl (,uM) Figure 9 ddC influx in U937 (-) and U937-R (0) cells
Assays were performed at 37 OC in 1.5 ml polypropylene mricrocentrifuge tubes using an 'oilstop' method as in [12] . Initial velocities were determined during the first 2 min, when the rate of influx was linear. Initial velocities were determined over a range of ddC concentrations from 1 to 500,M. Results are means+ S.D. of at least three experiments. 
